Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVN424 in Early Parkinson's Disease
NCT06006247Phase 2Completed
- Sponsor
- Cerevance
- Start
- Sep 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of solengepras in Parkinson's disease (PD), sponsored by Cerevance. Started Sep 2023; status: completed.
02
Drugs
solengepras
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06006247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006247.